NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) — Value Line, Inc. (NASDAQ: VALU) announced today that its Board of Directors declared on January 16, 2026 a quarterly cash dividend of $0.325 per common share, payable on February 10, 2026, to stockholders of record on January 26, 2026. The Company has 9,387,957 shares of common stock outstanding as of January 16, 2026. The Company also announced that the Board has appointed Dr. Alexander J. Swistel to its Board of Directors and as a member of the Board’s Audit Committee.         Value Line is a leading provider of investment research. The Value Line Investment Survey is one of the most widely used sources of independent equity research.         Value Line publishes proprietary investment research in separate print and digital formats.         Value Line provides these specialized services:...

NOTE TO READER – The news release of Endeavour Silver Corp. dated January 16, 2026, (the “News Release”) has been re-filed on SEDAR. The previously filed News Release had a typographical error on page 3 with respect to the AISC for Terronera. The consolidated AISC remains the same as the previously filed News Release. This news release replaces the previously filed News Release. VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its consolidated production and cost guidance for the Terronera, Guanaceví, and Kolpa mines, along with its capital and exploration budgets for 2026. All dollar amounts are in US dollars (US$) and ounces are troy ounces. 2026 Production and Cost Guidance Highlights In 2026, silver production from Terronera,...

BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the closing of its previously announced Company best efforts registered direct offering (“Offering”) of 7,040,000 ordinary shares at an offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. The gross proceeds to Tiziana from the Offering, before deducting estimated Offering expenses payable by Tiziana, were $8.8 million. For every ordinary share subscribed, participants will receive one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and...

MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies. BiPASS™ is the first study designed to gain marketing authorization for 68Ga-PSMA-PET2 imaging in the pre-biopsy setting. The prospective, open-label...

Company AnnouncementBased on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next stepsCOPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment among patients treated with epcoritamab monotherapy. EPCORE DLBCL-1 is the first Phase 3 study to demonstrate an improvement in PFS in patients with relapsed or refractory (R/R) diffuse large...

Partner Status empowers UK organisations to harness advanced digital capabilities without compromising sovereignty, security or sustainability LONDON, Jan. 16, 2026 (GLOBE NEWSWIRE) —  Rackspace Technology® (NASDAQ: RXT), a leading end-to-end hybrid cloud and AI solutions company, today announced its UK Sovereign Services has achieved the VMware Sovereign Cloud Partner Status, reinforcing Rackspace’s ability to store, process, and protect UK organisations’ most sensitive data. Rackspace Sovereign Services delivers a fully managed, private cloud platform designed specifically for organisations that require strict control over where data is located and how it is processed. Built on proven VMware technologies and operated from UK-based data centres, the service combines high availability, resilient networking, and integrated security...

Aspo Plc  ANNOUNCEMENT  16.1.2026          Aspo Plc: Share repurchase 16.1.2026       In the Helsinki Stock Exchange         Trade date           16.1.2026  Bourse trade         Buy  Share                  ASPO  Amount             1 000 SharesAverage price/ share    7,2400 EURTotal cost            7 240,00 EUR          Aspo Plc now holds a total of 120 552 shares  including the shares repurchased on 16.1.2026       The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052.          On behalf of Aspo Plc         Nordea Bank Oyj              Sami Huttunen Ilari Isomäki       For more information, please contact:  Erkka Repo,...

Elis announces the termination of the liquidity contract Puteaux, 16 January 2026 – Elis, the global leader in circular services at work, announces the termination of the liquidity contract agreed on December 1, 2023 with Oddo BHF (Group Natixis). The contract had been suspended since January 9, 2026, and was terminated by Elis with effect from January 14, 2026, in connection with the continuation of its share buyback program. As of January 14, 2026, the following resources appeared on the liquidity account:115,913 shares €3,197,794During the period from January 1, 2026 to January 8, 2026, the following resources were traded:On buy side, 48,667 shares for €1,174,141 (85 executions) On sell side, 64,304 shares for €1,562,380 (149 executions)As a reminder: 1)   The following resources appeared on the second half year statement...

Oslo, 16 January 2026: Scatec ASA will release its fourth quarter results on Friday 30 January 2026 at 07:00 CET. A presentation followed by a Q&A session will be held on the same day at 09:00 CET at Scatec’s headquarters at Skøyen Atrium III (1st floor), Askekroken 11, 0277 Oslo. The presentation and the Q&A session can be followed through a live webcast: Scatec webcast Q4 2025. For further information, please contact:For analysts and investors:Andreas Austrell, SVP IRandreas.austrell@scatec.com+47 974 38 686 For media:Meera Bhatia, SVP External Affairs & Communicationsmeera.bhatia@scatec.com+47 468 44 959 About Scatec  Scatec is a leading renewable energy solutions provider, accelerating access to reliable and affordable clean energy in emerging markets. As a long-term player, we develop, build, own, and operate renewable...